Documento técnico para la contención de transmisión de infecciones asociadas a resistencia a carbapenémicos
| dc.contributor.advisor | Fajardo, Hugo Alberto | spa |
| dc.contributor.advisor | Corredor, Sandra Milena | spa |
| dc.contributor.author | Recalde, Julia | spa |
| dc.date.accessioned | 2020-01-21T16:07:07Z | spa |
| dc.date.available | 2020-01-21T16:07:07Z | spa |
| dc.date.issued | 2019-12-16 | spa |
| dc.description.abstract | Antibacterial resistance is a public health problem associated with the wrong use of antimicrobials which puts people’s life in danger and generates over costs to the health system, hence it is very important to work on the development and establishment of Public health policies that allow surveillance of this problem, identification of risk factors and strategies aimed at the containment of carbapenemases to avoid intra and interhospital cross-transmission. This internship, carried out under agreement 237 of 2007 and of agreement 033 of 2008 of the “Consejo superior universitario” of the Universidad Nacional de Colombia, allowed us to extensively review the topic to raise the problem, carry out a systematic review of the structure, and allow the construction of technical recommendations. They could be used in clinical practice, it also raises the need to build a clinical practice guideline in the future. The internship is an additional resource within the personal training, in this context for the internist, allowing greater understanding of the mechanisms of bacterial resistance and deepening the knowledge of the bacteria producing carbapenemases, as well as effective strategies for their containment. The products created during the internship met the objectives proposed during this thesis Keywords: Enterobacteriaceae Resistant to Carbapenems, Public Health, Transmission, Technical Recommendations. | spa |
| dc.description.abstract | La resistencia a los antibacterianos es un problema de salud pública asociada al mal uso de los antimicrobianos o al abuso de los mismos que pone en peligro la vida de las personas y genera sobrecostos al sistema de salud, de allí que sea muy importante trabajar en el desarrollo e instauración de políticas de salud pública que permitan realizar vigilancia de esta problemática, identificación de factores de riesgo y estrategias dirigidas a la contención de carbapenemasas para evitar la transmisión cruzada intra e interhospitalaria. Esta pasantia, realizada en virtud del convenio 237 de 2007 y del acuerdo 033 de 2008 del Consejo Superior Universitario de la Universidad Nacional de Colombia, permitió revisar la temática a profundidad para plantear el problema, realizar una revision sistematica de literatura, y permitir la construcción de las recomendaciones técnicas que podrian ser usadas en la práctica clínica. La pasantía es un recurso adicional dentro de la formación personal, en este contexto para el internista, permitiendo mayor comprensión de los mecanismos de resistencia bacteriana y profundización en el conocimiento de las bacterias productoras de carbapenemasas, así como en estrategias efectivas para su contención. Se considera la realización los productos derivados de esta pasantía se dio cumplimiento a los objetivos propuestos en este trabajo de grado. Palabras clave: Enterobacteriaceae Resistentes a los Carbapenémicos, Salud Pública, Transmisión, Recomendaciones técnicas. | spa |
| dc.description.additional | Especialista en Medicina Interna | spa |
| dc.format.extent | 197 | spa |
| dc.format.mimetype | application/pdf | spa |
| dc.identifier.uri | https://repositorio.unal.edu.co/handle/unal/75502 | |
| dc.language.iso | spa | spa |
| dc.publisher.branch | Universidad Nacional de Colombia - Sede Bogotá | spa |
| dc.relation.references | 1. World Health Organization (Who). Report on the Burden of Endemic Health Care-Associated Infection Worldwide. WHO Libr Cat Data. 2011; 2. Haque M, Sartelli M, McKimm J, Bakar MA. Health care-associated infections – An overview. Infection and Drug Resistance. 2018. 3. Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: An environmental point prevalence study. Lancet Infect Dis. 2011; 4. Queenan AM, Bush K. Carbapenemases: The versatile β-lactamases. Clinical Microbiology Reviews. 2007. 5. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. The Lancet Infectious Diseases. 2013. 6. Escandón-Vargas K, Reyes S, Gutiérrez S, Villegas MV. The epidemiology of carbapenemases in Latin America and the Caribbean. Expert Review of Anti-Infective Therapy. 2017. 7. Birgand G, Johansson A, Szilagyi E, Lucet JC. Overcoming the obstacles of implementing infection prevention and control guidelines. Clinical Microbiology and Infection. 2015. 8. Lepelletier D, Batard E, Berthelot P, Zahar JR, Lucet JC, Fournier S, et al. Carbapenemase-producing enterobacteriae: Epidemiology, strategies to control their spread and issues. Revue de Medecine Interne. 2015. 9. Solter E, Adler A, Rubinovitch B, Temkin E, Schwartz D, Ben-David D, et al. Israeli national policy for carbapenem-resistant enterobacteriaceae screening, carrier isolation and discontinuation of isolation. Infection Control and Hospital Epidemiology. 2018. 10. Tacconelli E, Cataldo MA, Dancer SJ, De Angelis G, Falcone M, Frank U, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect. 2014; 11. WHO. Guidelines for the prevention and control of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in health care facilities. Who. 2017. 12. Magiorakos AP, Burns K, Rodríguez Baño J, Borg M, Daikos G, Dumpis U, et al. Infection prevention and control measures and tools for the prevention of entry of carbapenem-resistant Enterobacteriaceae into healthcare settings: Guidance from the European Centre for Disease Prevention and Control. Antimicrob Resist Infect Control. 2017; 13. van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence. 2017. 14. Richards (Chair) M, Cruickshank M, Cheng A, Gandossi S, Quoyle C, Stuart R, et al. Recommendations for the control of carbapenemase-producing Enterobacteriaceae (CPE): A guide for acute care health facilities: Australian Commission on Safety and Quality in Health Care. Infect Dis Heal. 2017; 15. Guh AY, Limbago BM, Kallen AJ. Epidemiology and prevention of carbapenem-resistant Enterobacteriaceae in the United States. Expert Review of Anti-Infective Therapy. 2014. 16. Ramos-Castañeda JA, Ruano-Ravina A, Barbosa-Lorenzo R, Paillier-Gonzalez JE, Saldaña-Campos JC, Salinas DF, et al. Mortality due to KPC carbapenemase-producing Klebsiella pneumoniae infections: Systematic review and meta-analysis: Mortality due to KPC Klebsiella pneumoniae infections. J Infect. 2018; 17. Otter JA, Burgess P, Davies F, Mookerjee S, Singleton J, Gilchrist M, et al. Counting the cost of an outbreak of carbapenemase-producing Enterobacteriaceae: an economic evaluation from a hospital perspective. Clin Microbiol Infect. 2017; 18. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, et al. Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2001; 19. Logan LK, Weinstein RA. The epidemiology of Carbapenem-resistant enterobacteriaceae: The impact and evolution of a global menace. J Infect Dis. 2017; 20. Lutgring JD, Limbago BM. The Problem of Carbapenemase-Producing-Carbapenem-Resistant-Enterobacteriaceae Detection. Journal of Clinical Microbiology. 2016. 21. Miriagou V, Cornaglia G, Edelstein M, Galani I, Giske CG, Gniadkowski M, et al. Acquired carbapenemases in Gram-negative bacterial pathogens: Detection and surveillance issues. Clinical Microbiology and Infection. 2010. 22. Oliver A. Impacto de la diseminación de Pseudomonas aeruginosa multirresistente productora de metalo-β-lactamasas en los hospitales: presente y futuro. Enferm Infecc Microbiol Clin. 2009; 23. Shen J, Pan Y, Fang Y, Sekaran SD. Role of the outer membrane protein OprD2 in carbapenem-resistance mechanisms of pseudomonas aeruginosa. PLoS One. 2015; 24. Meletis G, Exindari M, Vavatsi N, Sofianou D, Diza E. Mechanisms responsible for the emergence of carbapenem resistance in Pseudomonas aeruginosa. Hippokratia. 2012. 25. Santos WM Dos, Secoli SR. Economic burden of inpatients infected with Klebsiella pneumoniae carbapenemase. Einstein (Sao Paulo). 2019; 26. Bustos-Moya G, Josa-Montero D, Perea-Ronco J, Gualtero-Trujillo S, Ortiz-Aroca J, Novoa-Bernal Á, et al. Factors related to successful control of an outbreak by Klebsiella pneumonia-producing KPC-2 in an intensive care unit in Bogotá, Colombia. Infectio. 2016; 27. Villegas MV, Lolans K, Correa A, Kattan JN, Lopez JA, Quinn JP. First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing β-lactamase. Antimicrob Agents Chemother. 2007; 28. Ocampo AM, Vargas CA, Cienfuegos AV, Jiménez JN, Sierra PM. Molecular characterization of an outbreak of carbapenem-resistant Klebsiella pneumoniae in a tertiary care hospital in Medellín, Colombia. Biomedica. 2015; 29. Hussein K, Rabino G, Eluk O, Warman S, Reisner S, Geffen Y, et al. The association between infection control interventions and carbapenem-resistant Enterobacteriaceae incidence in an endemic hospital. J Hosp Infect. 2017; 30. Bustos-Moya G, Josa-Montero D, Perea-Ronco J, Gualtero-Trujillo S, Ortiz-Aroca J, Novoa-Bernal Á, et al. Factores relacionados con el control exitoso de un brote por Klebsiella pneumoniae productora de KPC-2 en una unidad de cuidado intensivo en Bogotá, Colombia. Infectio. 2016; 31. Adeolu M, Alnajar S, Naushad S, Gupta RS. Genome-based phylogeny and taxonomy of the ‘Enterobacteriales’: Proposal for enterobacterales ord. nov. divided into the families Enterobacteriaceae, Erwiniaceae fam. nov., Pectobacteriaceae fam. nov., Yersiniaceae fam. nov., Hafniaceae fam. nov., Morgane. Int J Syst Evol Microbiol. 2016; 32. Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, et al. Comparative review of the carbapenems. Drugs. 2007. 33. Kohanski MA, Dwyer DJ, Collins JJ. How antibiotics kill bacteria: From targets to networks. Nature Reviews Microbiology. 2010. 34. Bonfiglio G, Russo G, Nicoletti G. Recent developments in carbapenems. Expert Opinion on Investigational Drugs. 2002. 35. Hawkey PM, Livermore DM. Carbapenem antibiotics for serious infections. BMJ. 2012; 36. Codjoe F, Donkor E. Carbapenem Resistance: A Review. Med Sci. 2017 Dec 21;6(1):1. 37. Bedenić B, Plečko V, Sardelić S, Uzunović S, Godič Torkar K. Carbapenemases in gram-negative bacteria: Laboratory detection and clinical significance. BioMed Research International. 2014. 38. Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. Treatment of infections caused by extended-spectrum-beta-lactamase-, ampC-, and carbapenemase-producing enterobacteriaceae. Clinical Microbiology Reviews. 2018. 39. Thomson KS. Extended-spectrum-β-lactamase, AmpC, and carbapenemase issues. Journal of Clinical Microbiology. 2010. 40. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase producing Enterobacteriaceae. Emerg Infect Dis. 2011; 41. Perez F, Van Duin D. Carbapenem-resistant enterobacteriaceae: A menace to our most vulnerable patients. Cleve Clin J Med. 2013; 42. Váradi L, Luo JL, Hibbs DE, Perry JD, Anderson RJ, Orenga S, et al. Methods for the detection and identification of pathogenic bacteria: Past, present, and future. Chemical Society Reviews. 2017. 43. Nordmann P, Gniadkowski M, Giske CG, Poirel L, Woodford N, Miriagou V, et al. Identification and screening of carbapenemase-producing Enterobacteriaceae. Clinical Microbiology and Infection. 2012. 44. McMullen AR, Yarbrough ML, Wallace MA, Shupe A, Burnham CAD. Evaluation of genotypic and phenotypic methods to detect carbapenemase production in gram-negative bacilli. Clin Chem. 2017; 45. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant enterobacteriaceae: Epidemiology and prevention. Clinical Infectious Diseases. 2011. 46. Villegas MV, Lolans K, Correa A, Suarez CJ, Lopez JA, Vallejo M, et al. First detection of the plasmid-mediated class a carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America. Antimicrob Agents Chemother. 2006; 47. Montúfar-Andrade FE, Mesa-Navas M, Aguilar-Londoño C, Saldarriaga-Acevedo C, Quiroga-Echeverr A, Builes-Montaño CE, et al. Experiencia clínica con infecciones causadas por Klebsiella pneumoniae productora de carbapenemasa, en una institución de enseñanza universitaria en Medellín, Colombia. Infectio. 2016; 48. Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. Risk Factors and Clinical Impact of Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae . Infect Control Hosp Epidemiol. 2009; 49. Arnold RS, Thom KA, Sharma S, Phillips M, Kristie Johnson J, Morgan DJ. Emergence of Klebsiella pneumoniae carbapenemase-producing bacteria. South Med J. 2011; 50. Oteo J. ¿Deben implantarse programas de cribado de cepas productoras de carbapenemasas en pacientes que ingresan en la UCI? Enferm Infecc Microbiol Clin. 2017; 51. Richter SS, Marchaim D. Screening for carbapenem-resistant Enterobacteriaceae: Who, When, and How? Virulence. 2017. 52. Protonotariou E, Poulou A, Politi L, Sgouropoulos I, Metallidis S, Kachrimanidou M, et al. Hospital outbreak due to a Klebsiella pneumoniae ST147 clonal strain co-producing KPC-2 and VIM-1 carbapenemases in a tertiary teaching hospital in Northern Greece. Int J Antimicrob Agents. 2018; 53. Wang Z, Qin RR, Huang L, Sun LY. Risk Factors for Carbapenem-resistant Klebsiella pneumoniae Infection and Mortality of Klebsiella pneumoniae Infection. Chin Med J (Engl). 2018; 54. Forcina A, Baldan R, Marasco V, Cichero P, Bondanza A, Noviello M, et al. Control of infectious mortality due to carbapenemase-producing Klebsiella pneumoniae in hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017; 55. Manterola C, Astudillo P. Checklist for reporting of descriptive observational studies. MINCIR initiative. Int J Morphol. 2013; 56. Muñoz-Martín B, Higgins JPT, Green S E. Manual Cochrane de Revisiones Sistemáticas de Intervenciones, versión 5.1. 0. Man Cochrane Revis Sist Interv versión 510. 2012; 57. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. In: Journal of clinical epidemiology. 2009. 58. Fournier S, Desenfant L, Monteil C, Nion-Huang M, Richard C, Jarlier V, et al. Efficiency of different control measures for preventing carbapenemase-producing enterobacteria and glycopeptide-resistant Enterococcus faecium outbreaks: A 6-year prospective study in a French multihospital institution, January 2010 to December 2015. Eurosurveillance. 2018; 59. Hayden MK, Lin MY, Lolans K, Weiner S, Blom D, Moore NM, et al. Prevention of colonization and infection by klebsiella pneumoniae carbapenemase-producing enterobacteriaceae in long-term acute-care hospitals. Clin Infect Dis. 2015; 60. Mularoni A, Martucci G, Douradinha B, Campanella O, Hazen B, Medaglia A, et al. Epidemiology and successful containment of a carbapenem-resistant Enterobacteriaceae outbreak in a Southern Italian Transplant Institute. Transpl Infect Dis. 2019; 61. Cuzon G, Naas T, Truong H, Villegas MV, Wisell KT, Carmeli Y, et al. Worldwide diversity of klebsiella pneumoniae that produces β-lactamase blaKPC-2 Gene. Emerg Infect Dis. 2010; 62. Tomczyk S, Zanichelli V, Grayson ML, Twyman A, Abbas M, Pires D, et al. Control of CRE, CRAB, and CRPsA in Healthcare Facilities Healthcare Facilities: A Systematic Review and Reanalysis of Quasi-experimental Studies. Clin Infect Dis. 2018; 63. Centers for Diasease Control and Prevention. Facility Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE) November 2015 Update - CRE Toolkit. Centers Dis Control Prev. 2015; | spa |
| dc.rights | Derechos reservados - Universidad Nacional de Colombia | spa |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
| dc.rights.license | Atribución-NoComercial 4.0 Internacional | spa |
| dc.rights.spa | Acceso abierto | spa |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | spa |
| dc.subject.ddc | Medicina y salud::Cirugía, medicina regional, odontología, oftalmología, otología, audiología | spa |
| dc.subject.proposal | Enterobacteriaceae Resistentes a los Carbapenémicos ; Salud Pública ; Transmisión ; Recomendaciones técnicas | spa |
| dc.subject.proposal | Enterobacteriaceae Resistant to Carbapenems ; Public Health ; Transmission ; Technical Recommendations | eng |
| dc.title | Documento técnico para la contención de transmisión de infecciones asociadas a resistencia a carbapenémicos | spa |
| dc.type | Trabajo de grado - Especialidad Médica | spa |
| dc.type.coar | http://purl.org/coar/resource_type/c_bdcc | spa |
| dc.type.coarversion | http://purl.org/coar/version/c_ab4af688f83e57aa | spa |
| dc.type.content | Text | spa |
| dc.type.driver | info:eu-repo/semantics/masterThesis | spa |
| dc.type.version | info:eu-repo/semantics/acceptedVersion | spa |
| oaire.accessrights | http://purl.org/coar/access_right/c_abf2 | spa |